doubles the number of symptoms that women report. Implications for Practice:
Findings suggest that clinicians need to use a multidimensional symptom assessment tool in women with breast cancer at the initiation of RT. R adiation therapy (RT) is a common primary or adjuvant treatment for breast cancer. Radiation therapy reduces the risk of recurrence, 1 as well as long-term mortality. 1, 2 Prior to the initiation of RT, breast cancer patients have received 1 or more treatments (eg, surgery, chemotherapy [CTX] , hormone therapy, immunotherapy), depending on their age, 3 stage of disease, 3, 4 receptor status, 3, 4 and other tumor characteristics. 3, 4 Most women with early-stage disease receive RT following surgery. 1 However, some women will have received either neoadjuvant 4, 5 or adjuvant CTX 4, 5 prior to the initiation of RT. Each treatment for breast cancer results in a unique set of symptoms.
6Y8 Surgery is the primary treatment for early-stage breast cancer 1 and may produce significant arm morbidity (eg, lymphedema, 7 functional impairment 7, 9 ), as well as pain in the axilla or lateral chest wall. 7, 9, 10 Chemotherapy is associated with multiple symptoms (eg, fatigue, nausea, sweats 11Y13 ). In addition, women may experience sexual difficulties, 11 cognitive dysfunction, 13 sleep disturbances, 6 fatigue, 12,14 depression, 6 and hot flashes. 13, 15 Recent evidence suggests that women who receive treatment for breast cancer experience multiple symptoms that decrease their functional status and quality of life (QOL). 16Y18 However, the majority of research on symptoms in women undergoing treatment for breast cancer has focused on a single symptom such as fatigue, 14 menopausal symptoms, 13 or depression. 19 As cited in a recent review, 18 very little is known about the occurrence, severity, and distress associated with multiple symptoms in women with breast cancer because no studies were found that evaluated multiple symptoms in only women who underwent treatment for breast cancer. Of the 18 studies of multiple symptoms included in the review of Kim et al, 18 8 included patients with breast cancer. However, in these 8 studies, women with breast cancer were part of heterogeneous samples of patients with a variety of cancer diagnoses. Following the publication of this review, 18 Gwede and colleagues 20 reported the results of a study that attempted to identify distinct subgroups of patients who underwent adjuvant CTX for breast cancer based on their symptom experience. Using cluster analysis procedures, 2 distinct groups of patients were identified (ie, low and high symptom prevalence groups) based on patients' ratings of symptom occurrence on the Memorial Symptom Assessment Scale (MSAS). Although this study provides interesting information on the overall impact of multiple symptoms in women with breast cancer, no data were provided on the severity or distress associated with the various MSAS symptoms.
When women begin a new treatment for breast cancer, it is important to obtain pretreatment data on multiple symptoms and to identify patients who are at highest risk for the worst symptom profiles that warrant management. It is a plausible hypothesis that women with breast cancer who received CTX prior to RT, independent of other clinical characteristics, may have more symptoms at the initiation of RT than women who did not receive CTX independent of other clinical characteristics. Therefore, given the paucity of research on the occurrence, severity, and distress of multiple symptoms in patients with breast cancer, the purpose of this study was to evaluate for differences in symptom occurrence, severity, and distress, as well as QOL, between women who did and did not receive CTX prior to RT. In addition, the relationships among various demographic and clinical characteristics and total number of symptoms were evaluated using negative binomial regression.
n Materials and Methods
Patients and Settings
This study is part of a larger, longitudinal study of symptoms in oncology patients and their family caregivers. Symptoms and QOL data for women with breast cancer prior to the initiation of RT are presented in this article. Patients (n = 188) were included if they were adults (Q18 years of age); were able to read, write, and understand Norwegian; and were scheduled to receive RT for breast cancer or ductal carcinoma in situ. Patients were excluded if they were to receive RT to the brain or had a disease that affected their cognitive ability. Patients were recruited at the RT department of Oslo University Hospital, Norwegian Radium Hospital. The study was approved by the Regional Committee for Medical and Health Research Ethics, the Norwegian Directorate of Health, the privacy ombudsman at the hospital, and the institutional review board at Norwegian Radium Hospital.
Study Procedures
At the time of their first appointment in the RT department (approximately 8 days prior to the start of RT), patients were introduced to a member of the research team and provided with information about the study. After obtaining written informed consent, patients completed a number of self-report questionnaires to obtain information on demographic and clinical characteristics, as well as the Karnofsky Performance Status (KPS) scale, 21 the Self-administered Comorbidity Questionnaire (SCQ-19), 22 the MSAS, 23 and the Medical Outcomes Study Short Form (SF) 12. 24 Patients' medical records were reviewed for disease and treatment information.
Theoretical Framework
The Theory of Symptom Management (TSM) served as the theoretical framework for this study. 25 In 1994, the TSM was first introduced as the Symptom Management Model by faculty members in the School of Nursing at the University of California, San Francisco. 26 The 3 essential dimensions of the TSM are symptom experience, symptom management strategies, and symptom status outcomes. This study focuses on the symptom experience and symptom outcomes of women with breast cancer at the initiation of RT.
Instruments

DEMOGRAPHIC CHARACTERISTICS
Patients provided information on marital status (married, partnered, or unmarried/divorced/widowed), living situation (living alone or with someone including children), level of education (primary, secondary, college/university), and employment status (full/part time, sick leave/disability benefit, retired/other). Study nurses completed information on age.
CLINICAL CHARACTERISTICS
Stage of disease, treatment goal (curative/palliative), and types of previous treatments were obtained from the medical record. Previous cancer treatments were categorized as surgery, CTX, RT, hormonal therapy, and immunotherapy. Based on the patients' tumor (T), node (N), and metastasis (M) classification at the time of diagnosis, stage of disease was reclassified into 5 stages (0 = ductal carcinoma in situ to 4 = advanced-stage disease) using the TNM Classification of Malignant Tumours of the Union for International Cancer Control guidelines.
27,28
SELF-ADMINISTERED COMORBIDITY QUESTIONNAIRE
Patients completed the SCQ-19, which evaluated the number of, treatments for, and functional impact of health problems. The SCQ includes 16 common comorbidities and 3 optional conditions. A higher total score indicates a more severe comorbidity profile. Using the SCQ-19, patients were asked to indicate whether they had the comorbid condition (yes/no); if they had the condition, they were asked if they received treatment for it (yes/no); and finally if it limited their activities (yes/no). The total SCQ-19 score can range from 0 to 57 when the 3 optional items are used. 22 The SCQ is a clinical scale, with established validity and reliability 22 for the assessment of comorbidities in patients with chronic medical conditions. 22 The SCQ was translated into Norwegian using a standard forwardbackward translation 29 and was used in 2 previous studies in Norway. 30, 31 KPS SCORE Physical functioning was assessed using the KPS score, which can range from 0 (death) to 100 (the individual is able to carry on normal activities). As patients in this study were outpatients, the 40-to 100-point range of the scale was used. The KPS scale is used extensively and has a well-established validity and reliability. 21, 32 
MEMORIAL SYMPTOM ASSESSMENT SCALE
The MSAS contains a list of 32 physical and psychological symptoms that occur as a result of cancer or its treatment. 23 For each symptom, patients were asked to indicate whether they had the symptom during the past week (ie, occurrence). If they had experienced the symptom, they were asked to rate its frequency, severity, and distress. Symptom frequency was rated using a 4-point Likert scale (ie, 1 = rarely, 2 = occasionally, 3 = frequently, 4 = almost constantly), as well was severity (ie, 1= slight, 2 = moderate, 3 = severe, 4 = very severe). Symptom distress was rated using a 5-point Likert scale (ie, 0 = not at all, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe). 23 When analyzing these data, patients were coded as having the symptom if any 1 of 3 boxes was checked (ie, occurrence, severity, distress) even if the patient had checked ''do not have'' the symptom. All missing items were interpreted and coded to mean that the patient did not have the symptom. The reliability and validity of the MSAS are well established. 23 The MSAS was translated into Norwegian using a standard forward-backward translation. 29 Formal psychometric testing was not performed for the translated version, as the population in present study (ie, breast cancer) was part of the population in the original paper (ie, colon, prostate, breast, ovarian cancer) by Portenoy et al. 23 However, the Norwegian version was pilot tested with 10 cancer patients, and only minor linguistic adjustments were needed based on feedback from patients.
SHORT FORM 12
Quality of life was measured using the SF-12 questionnaire (version 1), which is a valid and reliable 24 measure of QOL that is used in both general 33 and cancer populations. 34, 35 The SF-12 has undergone extensive validity and reliability testing through a cross validation of item selection and scoring in 9 countries. 33 The Norwegian version is the result of a comprehensive and thorough forward-backward translation of the original. 36 The Norwegian version shows satisfactory validity and reliability. 33 The SF-12 consists of 12 questions about physical and mental health as well as overall health status. The questionnaire is scored into 2 components that measure physical (PCS) and mental health (MCS). 37 The SF-12 PCS and MCS summary measures are scored using norm-based methods from the 1998 general US population, with a mean of 50 (SD, 10). Scores greater than or less than 50 are interpreted as being greater than or less than the mean scores in the general US population. These scores are similar to cutoff scores for the Norwegian general population (ie, mean PCS, 50.3 [SD, 8.8] ; mean MCS, 50.6 [SD, 9.9]). 33 Higher PCS and MCS scores indicate better QOL. 37 
Data Analysis
All analyses were done using SPSS version 16 (SPSS Inc, Chicago, Illinois), and Stata version 11.1 (Stata Corp, College Station, Texas; 2010). Descriptive statistics were used to present demographic and clinical characteristics of the sample. Independent-sample t tests and exact # 2 analyses were used to test for differences in demographic and clinical characteristics and QOL scores between patients who did and did not receive CTX prior to RT. Exact # 2 tests were used to evaluate for differences in symptom occurrence rates between the 2 groups. For those patients who reported the occurrence of the symptoms, exact Mann-Whitney U tests were used to evaluate for differences in symptom severity and distress ratings between the 2 groups. When variables with 3 or more response categories had significant between-groups differences (P G .05), post hoc analyses were performed. The Benjamini-Hochberg 38 method was used to correct P values for multiple testing and to reduce the risk of making type I errors.
A negative binomial regression was performed using Stata to evaluate the effects of a number of study variables on the total number of symptoms endorsed on the MSAS (ie, dependent variable). Negative binomial regression was used rather than Poisson regression because the distribution of the count of the symptoms endorsed by the patients was strongly right skewed with overdispersion (the variance was greater than the mean). Only demographic and clinical variables that had a bivariate association (r) of 0.20 or greater (ie, KPS score, age, axillary lymph node dissection [ALND], previous CTX treatment, SCQ score) with the dependent variable were selected for joint entry into the regression analysis with the belief that this level of association was meaningful (4% shared variance) in this exploratory study. 39 Stage of disease was not entered into the regression analysis because of its clinical and statistical association with other covariates (ie, ALND, CTX). All of the variables were entered in the initial model. To construct a model that was parsimonious, variables were removed one at a time following the recommendations of Hosmer and Lemeshow 40 (2000) until only significant predictors remained in the final model. For all tests, P G .05 was considered as statistically significant.
n Results
Differences in Demographic Characteristics Between Women Who Did and Did Not Receive CTX
A total of 245 patients were approached, 85% signed the consent form, and of these patients 91% (n = 188) completed the questionnaires prior to RT. Patients who decided not to participate were significantly older (mean age, 61.5 [SD, 10.8] years; P = .015) than those who participated (mean age, 57.8 [SD, 9.2] years). The demographic characteristics of the sample are listed in Table 1 . Except for age (P G .001) and employment status (P G .001), no differences were found in any demographic characteristics between patients who did (n = 86) and did not (n = 102) receive CTX prior to RT. Patients who received CTX prior to RT were significantly younger (P G .001), and a higher percentage were on sick leave or disability benefit (P G .001).
Differences in Clinical Characteristics Between Women Who Did and Did Not Receive CTX
The clinical characteristics of the patients are listed in Table 2 . Patients who received CTX prior to RT had a significantly lower KPS score (P G .001). In addition, a higher percentage of these patients had stage 2 or 3 disease (P G .001) and were more likely to have had a mastectomy and ALND (P G .001), compared with women who did not receive CTX.
A higher percentage of women with stage 3 disease received CTX compared with women with stage 1 or 2 disease, and a higher percentage of women with stage 2 disease received CTX compared with stage 1 disease. Of the total number of patients who had received CTX (n = 86), 67% (n = 58) received it as adjuvant therapy to surgery, 28% (n = 24) received it as neoadjuvant CTX before surgery, and the remaining 5% (n = 4) had received CTX for a previous cancer diagnosis. Of the 5% (n = 10) of women with previous RT, 1 woman had received RT for another cancer diagnosis, 6 patients had received RT for breast cancer in the collateral breast, and the remaining 3 patients had received RT for breast cancer and were now scheduled for RT for metastatic disease.
Differences in Symptom Occurrence Rates and Total Number of Symptoms Between Women Who Did and Did Not Receive CTX
The occurrence rates for the 32 symptoms are listed in Table 3 . Of the 32 symptoms listed on the MSAS, 23 symptoms occurred in more than 20% of the total sample. The 5 symptoms with the highest occurrence rates in the total sample were lack of energy (63%), worrying (59%), difficulty sleeping (56%), feeling drowsy (53%), and sweats (52%). In the total sample, the mean number of symptoms was 9.2 (SD, 7.2). Patients who received CTX reported a significantly higher mean number of symptoms (12.6 [SD, 7.1]; P G .001) than patients who did not receive CTX (6.3 [SD, 5.8]) prior to RT. As shown in Table 3 , 18 of 32 symptoms occurred significantly more frequently in women who received CTX prior to RT compared with women who did not receive CTX.
Differences in Symptom Severity and Distress Score Between Women Who Did and Did Not Receive CTX
The severity scores for each of the MSAS symptoms, for women who had the symptom, are listed in Table 4 . Only 3 of the MSAS symptoms (ie, hair loss, changes in skin, difficulty swallowing) had significantly higher severity scores among women who received CTX prior to RT (all P G .001). The distress scores for each of the MSAS symptoms are listed in Table 5 ; no betweengroups differences were found.
Differences in QOL Scores Between Women Who Did and Did Not Receive CTX
As shown in the Figure, the mean PCS score on the SF-12 was significantly lower for patients who had received CTX prior to RT (P G .001) compared with patients who had not 33 found that both the physical and mental scores were significantly lower in the total sample of women with breast cancer (P G .001 and P = .022, respectively).
Predictors of the Total Number of Symptoms
All variables that were examined and found to have correlations of 0.2 or greater in absolute value with the total number of symptoms endorsed were included in the negative binomial regression analysis. As shown in Table 6 , only 3 covariates (ie, KPS, SCQ, CTX) remained as significant predictors in the multivariable model for the total number of symptoms (Likelihood ratio # 2 3 = 59.39, P G .00005). The predicted counts of symptoms were computed from the model for each observation and correlated with the empiric count. The Pearson correlation between the predicted and actual counts was 0.56, revealing that the percentage of variance in the total number of symptoms predicted by the model was 31%. 41 An evaluation of the incidence rate ratio suggests that, for each 10-point decrease in KPS score, the predicted total number of symptoms endorsed increased by 13% (P = .007, KPS reversed and rescaled to improve interpretation). For each 1-unit increase in SCQ score, the predicted total number of symptoms endorsed increased by 5% (P = .004). Patients who received CTX prior to RT endorsed 73% more symptoms than patients who did not receive CTX (P G 0.0005). Considering the relative improvement of fit for each of these 3 variables 43 followed by SCQ score (0.008) and KPS (0.007).
n Discussion
To our knowledge, this study is the first to evaluate for differences in the occurrence, severity, and distress of multiple symptoms in patients with breast cancer who did and did not receive CTX prior to RT. Consistent with our a priori hypothesis, women who received CTX prior to RT reported twice the number of symptoms than women who had not received CTX. When this sample of women with breast cancer is evaluated as a whole, their mean number of symptoms (ie, 9.2) is within the range of 6.5 (Kim et al 44 ) and 18 (Harding et al 45 ) symptoms, reported in previous studies that used the MSAS.
44Y47
Differences in the mean number of symptoms across all these studies may be related to differences in cancer diagnoses, stage of the disease, treatment modalities, presence of comorbidities, and setting of care (eg, inpatients vs outpatients). Additional research is warranted to determine how each of these factors influences the symptom experience of oncology patients within and across cancer diagnoses.
Differences in Symptom Occurrence Rates
For 18 of the 32 symptoms on the MSAS (56.3%), women who received CTX prior to RT reported significantly higher occurrence rates than women who did not receive CTX. The largest between-groups differences in occurrence rates were for hair loss (48% difference), numbness/tingling (47% difference), ''food tastes different'' (39% difference), ''I don't look like myself'' (39% difference), and dry mouth (34% difference), which are clinically important symptoms more likely to occur following the administration of CTX than after other forms of cancer treatment.
An interesting finding, particularly from a clinical perspective, is that for 7 of the 11 symptoms (64%) that occurred (ie, worrying, difficulty sleeping, sweats, pain, difficulty concentrating, problems with sexual interest, and feeling bloated) in more than 40% of the total sample at the initiation of RT (Table 3) , no between-groups differences were found in occurrence rates. This finding suggests that these symptoms are common in all patients with breast cancer regardless of previous cancer treatment. For example, the relatively high occurrence of worrying in both groups may be related to the initiation of a new treatment. This finding is consistent with a systematic review of psychological distress during RT, 48 in which Stiegelis and colleagues 48 noted that 10% to 20% of patients experience anxiety prior to RT. However, the occurrence rate for worrying in the present study is much higher (59%) than that reported by Stiegelis et al, 48 but within the range of 32% 47 and 75% 46 reported in previous studies that used the MSAS. Given the high occurrence rate for worrying, additional research is needed to determine the specific etiology of this symptom.
It is reasonable to suggest that the high occurrence rates for difficulty sleeping and difficulty concentrating in both groups of women may be associated with worrying. In fact, several studies have demonstrated that these symptoms represent a ''symptom cluster'' in cancer patients. 44, 49 The occurrence rates for sweats were equally high in both groups of women. Although detailed information on the causes of sweats was not obtained, it is plausible that many of the women who received CTX prior to RT were experiencing a ''chemically induced'' menopause. 11, 50 In addition, because women who did not receive CTX were significantly older (60.7 years), their sweats may be attributed to biological menopause or previous or concurrent hormonal therapy. 15 In a similar manner, the high rates of feeling bloated may be part of a menopausal symptom cluster.
Because detailed information was not obtained about the causes of pain, it is difficult to explain the high occurrence rates for pain in both groups of women. In the women who did not receive CTX, pain may be associated with their surgical procedure or subsequent rehabilitation activities. Women who received CTX may be experiencing pain from CTX-induced neuropathy. 47, 51 This hypothesis is supported by the higher occurrence rate for numbness and tingling (59%) in these women. In addition, the high rates of pain in both groups of women may be related to other chronic medical conditions. In fact, in this sample, 19% of women reported arthritis, and 36% reported back and neck pain. Additional research is warranted to determine the exact causes, characteristics, and impact of pain in both groups of women.
Differences in Symptom Severity Rates
A surprising finding from this study is that, when between-groups differences in symptom severity scores were evaluated in women who had the symptom (Table 4 ), no differences in severity scores were found for 91% (29/32) of the symptoms. Across these 29 symptoms, severity scores were in the mild to moderate range. Overall symptom severity scores in this sample were similar to those reported by Kim and colleagues 44 in a sample of patients with breast and prostate cancer at the initiation of RT, slightly higher than those reported for patients with a variety of cancer diagnoses during the first year following a cancer diagnosis (15.4% had breast cancer), 49 but lower than for a sample of patients with advanced cancer. 52 Except for difficulty sleeping, the 5 symptoms with the highest severity scores (ie, hair loss, difficulty sleeping, sweats, problems with sexual interest, ''I don't look like myself'') were different symptoms from the 5 most prevalent symptoms (ie, lack of energy, worrying, difficulty sleeping, feeling drowsy, sweats). Three of the 5 symptoms with the highest severity scores (ie, hair loss, problems with sexual interest, ''I don't look like myself'') that were in the moderate to severe range are associated with changes in body image.
Both the occurrence rates and severity scores for sweats in this study were high. This finding is consistent with a previous report by Kim and colleagues, 44 who found similar occurrence rates and severity scores for this symptom in a sample of patients with breast and prostate who underwent RT. Findings from these 2 studies suggest that the impact of cancer and its treatment on hormonal balance warrants investigation in future studies.
Although some of the symptoms with the highest severity scores had the lowest occurrence rates (ie, hair loss, changes in skin), they warrant assessment in women who have these symptoms. Clinicians need to recognize that the most prevalent symptoms may not be the most severe symptoms for women with breast cancer at the initiation of RT.
Differences in Symptom Distress
No between-groups differences were found in any of the symptom distress scores for patients who reported the symptoms. For the majority of the symptoms, the distress scores were in the mild range. Symptom distress scores for this sample were comparable to those reported by Molassiotis and colleagues 47 in a sample of patients with a variety of cancer diagnoses but lower than those reported by patients with advanced cancer. 52 Except for difficulty sleeping, the 5 most distressing symptoms (ie, ''I don't look like myself,'' problems with sexual interest, hair loss, swelling of arms and legs, difficulty sleeping) were not the same as the most prevalent symptoms. However, 4 of these symptoms (ie, difficulty sleeping, problems with sexual interest, hair loss, ''I don't look like myself'') were also the most severe. Longitudinal data are needed to better understand the trajectory of these symptoms, as the most distressful symptoms were all rare symptoms, except from difficulty sleeping. Additional research is needed to determine what factors contribute to patients' perception of symptoms severity and distress, because in contrast to this study Molassiotis et al 47 found that the symptoms with the highest severity and distress ratings were also the most prevalent.
Difficulty sleeping is the only symptom that was in the top 5 symptoms for occurrence, severity, and distress in this study. Recent evidence suggests that sleep disturbance occurs in 30% to 88% of oncology patients and has a significant impact on patients' mood and QOL. 
Predictors of the Total Number of Symptoms
Consistent with previous reports, a higher SCQ score 54 and a lower KPS score 17 were associated with a higher number of symptoms in this study. Consistent with our a priori hypothesis, the variable that most improved the fit of the negative binomial regression model for the total number of symptoms was receipt of CTX (2.2% improvement in fit; Table 6 ). Compared with previous studies, younger age, 34, 55 living alone, 55 and less education 55, 56 were not associated with a higher number of symptoms in this study. These inconsistent findings may be related to differences in the instruments used to measure symptoms, samples with single versus multiple cancer diagnoses, sex, stage of the patient's disease, or place in the treatment trajectory. Additional research is warranted to determine the demographic and clinical characteristics that contribute to the higher number of symptoms in oncology patients at the initiation of RT.
Differences in QOL
Although no between-groups differences were found in MCS scores, patients who received CTX prior to RT reported significantly lower PCS scores (P G .001) than patients who did not receive CTX. This finding is supported by the fact that, for 17 of the 18 symptoms that had higher occurrence rates in the patients who received CTX, they were symptoms that Portenoy et al 23 had labeled ''physical symptoms.'' In the original report on the MSAS, 23 6 symptoms (ie, worrying, feeling sad, feeling nervous, difficulty sleeping, feeling irritable, and difficulty concentrating) were identified as contributing to a measure of global psychological distress. In this study, with the exception of feeling sad, no between-groups differences were found in these symptoms, and they occurred in between 31% and 59% of the women. This finding suggests that, at the initiation of RT, a significant proportion of women experience psychological distress and is consistent with previous reports that document high rates of anxiety 48 and depression 57 in patients at the initiation of RT.
When the mean PCS and MCS scores for the total sample in this study were compared with Norwegian normative data from the general population, 33 women with breast cancer had significantly poorer QOL. The importance of appropriate symptom management strategies for these women must be taken seriously, as a strong association between numbers of symptoms, psychological distress, performance status, and overall QOL was found in a heterogeneous sample of cancer patients. 46 
Limitations
Several study limitations need to be acknowledged. First, detailed information on the causes and characteristics of the various MSAS symptoms was not obtained, which limits our ability to determine the specific etiologies for the most common, severe, and distressing symptoms. Furthermore, information on symptom management interventions was not obtained, so some of the between-groups differences or lack of differences may be attributable to differences in symptom management interventions. Despite these limitations, this study provides detailed information on the occurrence, severity, and distress of multiple symptoms in women with breast cancer at the initiation of RT.
Implications for Practice
Findings from this study suggest that clinicians need to perform comprehensive assessments of multiple symptoms in breast cancer patients at the initiation of RT. In addition, clinicians need to be aware that women previously treated with CTX are at greater risk for an increased number of symptoms. However, for any given patient, the most prevalent symptoms may not always be the most severe and distressing symptoms. Therefore, multiple dimensions of the symptom experience should be assessed using an instrument such as the MSAS, which is relatively easy for patients to complete and provides clinicians with a large amount of useful information.
Implications for Research
Longitudinal data on occurrence, severity, and distress for the most frequent symptoms in this study warrant further investigation. These types of data would facilitate the development and testing of interventions for symptoms that increase and/or persist during and following RT. In addition, the etiology for and characteristics of each of the most common, most severe, and most distressing symptoms need to be evaluated in future studies.
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